**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 72456

**Manuscript Type:** LETTER TO THE EDITOR

**Is CA19-9 effective in predicting chemotherapeutic response in patients with synchronous liver metastases with colorectal cancer?**

Demirli Atici S *et al*. CA19-9 in predicting chemotherapeutic response

Semra Demirli Atici, Erdinc Kamer

**Semra Demirli Atici, Erdinc Kamer,** Department of General Surgery, University of Health Sciences Tepecik Training and Research Hospital, İzmir 35180, Turkey

**Author contributions:** Demirli Atici S and Kamer E wrote the manuscript; Kamer E reviewed and supervised the manuscript preparation; Both authors read and agreed to the published version of the manuscript.

**Corresponding author: Semra Demirli Atici, MD, Surgeon,** Department of General Surgery, University of Health Sciences Tepecik Training and Research Hospital, Güney Mahallesi, 1140/1 Sokak No:1 Yenişehir/Konak, İzmir 35180, Turkey. smrdemirli@hotmail.com

**Received:** October 22, 2021

**Revised:** December 11, 2021

**Accepted:** January 13, 2022

**Published online:** January 28, 2022

**Abstract**

Evaluation of response to chemotherapy in colorectal cancer patients with synchronous liver metastases is important in terms of treatment management. In this Letter to the Editor, several issues in the article are discussed. For the comparison of carbohydrate antigen 19-9 (CA19-9) values referenced in the study, the patient group was not matched for cancer stage. Therefore, it may be more appropriate to select and compare CA19-9 values in patients with same-stage cancer.

**Key Words:** Colorectal cancer; Carbohydrate antigen 19-9; Liver metastasis of colorectal cancer; Synchronous liver metastasis; Chemotherapy; Metastatic colorectal cancer

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Demirli Atici S, Kamer E. Is CA19-9 effective in predicting chemotherapeutic response in patients with synchronous liver metastases with colorectal cancer? *World J Gastroenterol* 2022; 28(4): 500-501

URL: https://www.wjgnet.com/1007-9327/full/v28/i4/500.htm

DOI: https://dx.doi.org/10.3748/wjg.v28.i4.500

**Core Tip:** It is important to evaluate synchronous liver metastases of colorectal cancer (CRC) and to determine the response to chemotherapy in patients. Based on findings from such, the optimal treatment method is selected for each patient. The scoring system described in the study, created through a combination of radiology and laboratory parameters, can guide treatment. However, we think that it would be more appropriate to discuss the results of this study in the context of other studies conducted with patients with stage IV CRC.

**TO THE EDITOR**

Ma *et al*[1] recently published a retrospective study on the emerging role of a magnetic resonance imaging (MRI)-radiomics signature to detect the predictive efficiency of models for chemotherapeutic response in colorectal cancer (CRC) patients with synchronous liver metastasis (SLM) and avoid ineffective chemotherapy.

Carbohydrate antigen 19-9 (CA19-9) has been routinely studied in patients with CRC, and in the study by Ma *et al*[1] the measurement of CA19-9 was found to be significant between the disease non-response (non-DR) and disease response (DR) to chemotherapy groups (*P* = 0.045). The authors showed that CA19-9 Levels were higher in the DR (63.3%) group than in the non-DR group (43.4%). The authors reported that CA19-9 is a promising indicator for predicting response to chemotherapy, citing the study by Zhou *et al*[2]. However, the study design used by Zhou *et al*[2] had included patients with stage III CRC, while the study by Ma *et al*[1] focused on patients with stage IV CRC.

Although it is known that high CA19-9 Levels are a poor-prognosis factor in untreated stage IV CRC patients, routine measurement of CA19-9 in colon cancers is not recommended by the American Society of Clinical Oncology (ASCO) guidelines due to insufficient evidence[3,4]. As such, we believe that it would be more appropriate to discuss the results of the study by Ma *et al*[1] in the context of other studies conducted with stage IV CRC patients[4,5].

**REFERENCES**

1 **Ma YQ**, Wen Y, Liang H, Zhong JG, Pang PP. Magnetic resonance imaging-radiomics evaluation of response to chemotherapy for synchronous liver metastasis of colorectal cancer. *World J Gastroenterol* 2021; **27**: 6465-6475 [PMID: 34720535 DOI: 10.3748/wjg.v27.i38.6465]

2 **Zhou W**, Yang F, Peng J, Wang F, Lin Y, Jiang W, Yang X, Li L, Lu Z, Wan D, Pan Z, Fan W. High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy. *J Cancer* 2019; **10**: 3810-3818 [PMID: 31333798 DOI: 10.7150/jca.31375]

3 **Locker GY**, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol* 2006; **24**: 5313-5327 [PMID: 17060676 DOI: 10.1200/JCO.2006.08.2644]

4 **Hidaka E**, Maeda C, Nakahara K, Wakamura K, Ishiyama Y, Shimada S, Seki J, Takano Y, Oae S, Enami Y, Sawada N, Ishida F, Kudo SE. High Serum CA19-9 Concentration Predicts Poor Prognosis in Elderly Patients with Stage IV Colorectal Cancer. *Gastrointest Tumors* 2019; **5**: 117-124 [PMID: 30976583 DOI: 10.1159/000493793]

5 **Yu Z**, Chen Z, Wu J, Li Z, Wu Y. Prognostic value of pretreatment serum carbohydrate antigen 19-9 level in patients with colorectal cancer: A meta-analysis. *PLoS One* 2017; **12**: e0188139 [PMID: 29141049 DOI: 10.1371/journal.pone.0188139]

**Footnotes**

**Conflict-of-interest statement:** The author(s) declare having no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** October 22, 2021

**First decision:** December 1, 2021

**Article in press:** January 13, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Turkey

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Camacho S, Liu Z, Ros J, Wan XH **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Gong ZM



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**